The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

December 7, 2021 • By Jeffrey Curtis, MD, MS, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Taken together, this series of presentations highlights important safety concerns with JAK inhibitor therapy but should be interpreted in light of important considerations regarding generalizability. The trial intentionally recruited only patients with RA at high CVD risk; even in these higher risk individuals, it was only the patients at highest risk (e.g., those older than 65, current or former smokers, past VTE event) who experienced a risk that was greater than corresponding risks for TNF inhibitors. Despite the newly narrowed FDA indication and updated Boxed Warnings for JAK inhibitors, it is likely that many clinicians will still find JAK inhibitors to be an important option for many patients with RA, especially those without strong CV or VTE risk factors.

You Might Also Like
  • COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
  • New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
Explore This Issue
January 2022

PREVENTION

Switching topics, the potential to prevent or delay progression to RA in at-risk but asymptomatic patients who may have subclinical disease is a topic of high interest. Rheumatologists and their patients likely would value treatment with demonstrable effectiveness for prevention.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Abstract 0957: Vitamin D and marine n-3 fatty acid supplementation and prevention of autoimmune disease in the VITAL randomized controlled trial5

Research by Hahn J, et al.

The association between vitamin D sufficiency and a reduced risk of incident autoimmune disease has been a long-observed phenomenon. However, past work supporting this association has suffered from non-interventional study designs, inadequately dosed vitamin D regimens (e.g., 400 IU/day) or concerns regarding the potential for substantial confounding.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The large-scale Vitamin D and Omega-3 Trial (VITAL), a U.S., double-blind, placebo-controlled trial, randomized men who were at least 50 years old and women who were at least 55 years old to vitamin D3 (2,000 IU/d) and/or n-3 fatty acids (1,000 mg/d) or placebo. This plenary presentation reported the effects of vitamin D3 and n-3 fatty acids upon the incidence of autoimmune disease. New-onset autoimmunity was reported by participants annually and then confirmed by medical record review by expert physicians for classification criteria.

During median follow-up of 5.3 years, confirmed autoimmune disease was diagnosed in 117 participants in the vitamin D3 group and 150 in the placebo group (HR 0.78, 95% CI 0.61–1.00, P=0.04). Confirmed autoimmune disease was diagnosed in 123 participants in the n-3 fatty acids group and 144 in the placebo group (HR 0.85, 95% CI 0.67–1.09). RA and polymyalgia rheumatic were among the more commonly occurring incident autoimmune conditions.

Results from this study provide new experimental evidence that sufficiently dosed vitamin D results in a lower risk for new-onset autoimmune conditions, and these findings likely represent an important public health message. This trial’s results may offer rheumatologists the opportunity to provide practical advice for those who may be concerned about developing autoimmune conditions in the future.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Research Reviews, Rheumatoid Arthritis Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RAIssue: January 2022

You Might Also Like:
  • COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
  • New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)